Ventolin

How to order Ventolin

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Ventolin on Prescriptsy

Ventolin is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Ventolin is the most widely recognised reliever inhaler in the United Kingdom, containing salbutamol (also known as albuterol in some countries), a short-acting beta-2 adrenergic agonist (SABA) manufactured by GSK.

It is licensed for the relief and prevention of bronchospasm in patients with reversible obstructive airways disease, including asthma, chronic obstructive pulmonary disease (COPD), and exercise-induced bronchoconstriction.

The Ventolin Evohaler is a pressurised metered-dose inhaler (pMDI) delivering 100 micrograms of salbutamol per actuation via a CFC-free HFA-134a propellant.

Asthma affects approximately 5.4 million people in the United Kingdom, and COPD affects an estimated 1.2 million.

Together, these conditions place an enormous burden on individuals, families, and the NHS, accounting for over 100,000 hospital admissions per year.

Salbutamol has been in continuous clinical use since 1969 and remains the global standard of care for acute bronchospasm relief.

This page provides a comprehensive clinical overview of Ventolin, including how it works, correct inhaler technique, dosing guidance, side effects, safety warnings, the broader context of asthma management, and how to obtain a prescription in the UK.

Important safety information about Ventolin

Before reading further, note the following key safety points about Ventolin.

• Ventolin is a reliever inhaler for acute symptoms only. It does not treat the underlying inflammation of asthma. Most patients with asthma also need a regular preventer inhaler.
• Using Ventolin more than 3 times a week or waking at night with symptoms indicates poorly controlled asthma. Seek a medical review rather than increasing reliever use.
• If an asthma attack does not respond to your usual number of puffs, call 999 immediately.
• Keep your Ventolin inhaler with you at all times.

What is asthma

Asthma is a chronic inflammatory disease of the airways characterised by variable episodes of wheeze, breathlessness, chest tightness, and cough.

The underlying pathophysiology involves chronic eosinophilic airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction caused by smooth muscle contraction, mucosal oedema, and mucus hypersecretion.

Triggers vary between individuals and may include allergens (house dust mites, pollen, pet dander, mould), respiratory infections, cold air, exercise, air pollution, occupational exposures, and emotional stress.

Without adequate anti-inflammatory treatment, chronic inflammation leads to airway remodelling, including subepithelial fibrosis, smooth muscle hypertrophy, and goblet cell hyperplasia, which progressively reduce the reversibility of airflow obstruction.

This underscores the importance of early and sustained preventer therapy to protect long-term lung function, rather than relying solely on reliever medication to manage symptoms as they arise.

Asthma in the UK

According to Asthma + Lung UK, the UK has one of the highest prevalence rates of asthma globally.

Approximately 12% of adults and 13% of children in the UK have been diagnosed with asthma.

The condition accounts for over 60,000 hospital admissions and approximately 1,400 deaths per year.

The National Review of Asthma Deaths (NRAD) identified preventable factors in the majority of asthma deaths, including failure to prescribe or use regular preventer therapy, over-reliance on SABA relievers, lack of personalised asthma action plans, and failure to attend routine reviews.

These findings have shaped current NICE and BTS/SIGN recommendations for safer prescribing practices.

How Ventolin works: mechanism of action

Salbutamol is a selective beta-2 adrenergic receptor agonist.

Beta-2 receptors are G-protein coupled receptors found abundantly on bronchial smooth muscle cells, as well as on mast cells, Clara cells, type II pneumocytes, and vascular endothelium in the lungs.

When salbutamol binds to beta-2 receptors on bronchial smooth muscle, it activates the stimulatory G-protein (Gs), which in turn activates adenylate cyclase.

This enzyme catalyses the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), an intracellular second messenger.

Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple target proteins involved in smooth muscle contraction.

The key downstream effects include inhibition of myosin light chain kinase (preventing actin-myosin cross-bridge formation), activation of calcium-activated potassium channels (causing membrane hyperpolarisation), and sequestration of intracellular calcium into the sarcoplasmic reticulum.

The net result is rapid relaxation of bronchial smooth muscle and relief of bronchospasm.

In addition to bronchodilation, salbutamol has several non-bronchodilator effects that contribute to symptom relief.

It inhibits the release of inflammatory mediators (histamine, leukotrienes, prostaglandins) from mast cells, enhances mucociliary clearance by increasing ciliary beat frequency, reduces microvascular leakage and airway oedema, and may improve diaphragmatic contractility.

These effects are secondary to its primary bronchodilator action but are clinically relevant during acute exacerbations.

The onset of action of inhaled salbutamol is within 1 to 3 minutes, with peak bronchodilation at 15 to 20 minutes.

The duration of action is approximately 4 to 6 hours.

The rapid onset and short duration distinguish salbutamol from long-acting beta-2 agonists (LABAs) such as salmeterol and formoterol, which are used for maintenance therapy rather than acute relief.

Clinical evidence and national guidelines

Salbutamol has been used clinically for over 50 years and is one of the most extensively studied bronchodilators in respiratory medicine.

Its efficacy, safety, and ease of administration have made it the universal first-line treatment for acute bronchospasm across all major international guidelines, including NICE, BTS/SIGN, GINA, and the European Respiratory Society (ERS).

NICE guideline NG80 (Asthma: diagnosis, monitoring and chronic asthma management) recommends that all patients with asthma should have access to a SABA reliever inhaler for as-needed use.

However, NICE and BTS/SIGN now emphasise that over-reliance on SABA therapy is associated with increased morbidity and mortality.

The dispensing of 3 or more SABA inhalers per year should trigger a clinical review, and the dispensing of 6 or more per year indicates significantly increased risk of poor outcomes.

The 2019 GINA strategy report introduced the recommendation that SABA-only treatment (without an inhaled corticosteroid) is no longer recommended even in mild asthma, representing a paradigm shift in asthma management.

BTS/SIGN guidelines outline a stepwise approach to asthma treatment. At Step 1, a SABA reliever is used as needed.

From Step 2 onwards, an inhaled corticosteroid preventer is added. SABA use frequency is a key indicator of asthma control and guides treatment escalation.

In COPD management, NICE guideline NG115 recommends short-acting bronchodilators (SABA or short-acting muscarinic antagonists) as initial reliever therapy, with escalation to long-acting bronchodilators and inhaled corticosteroids based on exacerbation history and spirometric severity.

Correct inhaler technique

Effective use of Ventolin depends critically on correct inhaler technique.

Research consistently shows that up to 90% of patients using a pMDI make at least one significant error that reduces drug delivery to the lungs.

Poor technique is one of the most common and correctable causes of apparently uncontrolled asthma. Follow these steps for each dose.

• Remove the mouthpiece cap and check the mouthpiece is clean and free of debris.
• Shake the inhaler vigorously for 5 seconds. If the inhaler has not been used for 5 or more days, release 2 test sprays into the air away from your face.
• Hold the inhaler upright with your thumb on the base and your index finger on the top of the canister.
• Breathe out gently and fully, away from the inhaler mouthpiece.
• Place the mouthpiece between your teeth and close your lips around it to form a tight seal.
• As you begin to breathe in slowly and deeply through your mouth, press the canister down once to release one dose.
• Continue breathing in slowly and steadily for 3 to 5 seconds after the dose is released.
• Remove the inhaler from your mouth, close your mouth, and hold your breath for about 10 seconds (or as long as is comfortable).
• If a second puff is needed, wait about 30 seconds before repeating the process from the shaking step.
• Replace the mouthpiece cap after use.

Using a spacer device

A spacer device is a plastic chamber that attaches to the inhaler mouthpiece and holds the aerosol cloud, allowing the patient to breathe it in more slowly and eliminating the need for precise hand-breath coordination.

Spacers increase lung deposition from approximately 10 to 15% (pMDI alone) to 20 to 25% and reduce oropharyngeal deposition.

They are recommended for all children, elderly patients, anyone who finds coordination difficult, and during acute asthma attacks (where the tidal breathing technique through a spacer is as effective as nebulisation for mild to moderate exacerbations).

The Volumatic and Aerochamber Plus are commonly used spacers in the UK.

Side effects of Ventolin

Common side effects

Fine tremor of the hands is the most frequently reported side effect, caused by beta-2 receptor activation on skeletal muscle.

It is dose-dependent and usually subsides with continued use. Headache is common.

Tachycardia (fast heartbeat) and palpitations may occur, particularly at higher doses or in patients who are sensitive to sympathomimetic agents.

These effects are generally mild, transient, and do not require discontinuation of treatment.

Uncommon side effects

Muscle cramps, throat irritation, and a slight unpleasant taste may be experienced.

Transient hypokalaemia (low blood potassium) results from beta-2 receptor-mediated intracellular potassium shift and is usually clinically insignificant at standard inhaled doses.

However, during the treatment of severe acute asthma with repeated nebulised or intravenous salbutamol, hypokalaemia may become clinically relevant and contribute to cardiac arrhythmias.

Monitoring of serum potassium and cardiac rhythm is standard in hospital acute asthma protocols.

Rare side effects

Paradoxical bronchospasm (sudden worsening of wheeze after inhalation) is rare but recognised.

If this occurs, stop using the inhaler, use an alternative bronchodilator if available, and seek immediate medical advice. Hyperactivity and behavioural changes may occur in children.

Cardiac arrhythmias, including atrial fibrillation and supraventricular tachycardia, are rare and typically associated with high-dose or systemic administration. Hypersensitivity reactions including urticaria, angioedema, and bronchospasm are very rare.

When to seek medical help

Contact your GP, pharmacist, or NHS 111 if side effects are persistent or troublesome.

Seek emergency care by calling 999 or attending A&E if your inhaler does not relieve your symptoms, if you experience chest pain, a very fast or irregular heartbeat, worsening breathlessness, swelling of the face, lips, or tongue, or if you are using your reliever inhaler more than every 4 hours during an acute attack.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

SABA over-reliance

The NRAD and subsequent safety reviews have identified SABA over-reliance as a major contributor to preventable asthma deaths.

Patients who rely heavily on their reliever inhaler without adequate preventer therapy are at significantly increased risk of severe exacerbations and death.

NICE recommends that prescribers review any patient who is dispensed 3 or more SABA inhalers per year, and consider this a signal of suboptimal asthma control.

If you find yourself reaching for your Ventolin inhaler frequently, this is a clear signal to book an asthma review, not to request more inhalers.

Cardiovascular cautions

Salbutamol should be used with caution in patients with hyperthyroidism, ischaemic heart disease, cardiac arrhythmias, hypertension, or hypertrophic obstructive cardiomyopathy.

At high doses, beta-2 agonists can cause tachycardia, palpitations, and QTc prolongation.

Non-cardioselective beta-blockers (such as propranolol) should be avoided in patients with asthma, as they may precipitate severe, refractory bronchospasm.

If a beta-blocker is required, a cardioselective agent (such as bisoprolol) should be used with caution and under close monitoring.

Diabetes and metabolic effects

High-dose salbutamol (particularly nebulised or intravenous formulations) can cause transient hyperglycaemia and hypokalaemia.

Patients with diabetes should be aware that blood glucose may rise temporarily during acute asthma treatment.

These effects are dose-dependent and generally resolve once the acute episode has been managed.

Pregnancy and breastfeeding

Inhaled salbutamol at standard doses has been used extensively during pregnancy with no evidence of increased foetal risk.

BTS/SIGN and NICE guidelines emphasise that acute asthma during pregnancy is far more dangerous to mother and baby than the use of reliever medication, and that pregnant women should be actively encouraged to continue using their inhalers.

Salbutamol enters breast milk in small amounts, but at standard inhaled doses the quantity transferred to the infant is negligible.

Breastfeeding mothers should continue to use Ventolin as normal.

How to get a Ventolin prescription in the UK

Ventolin is classified as a prescription-only medicine (POM) in the UK.

It is most commonly prescribed by GPs or asthma nurses as part of a comprehensive asthma management plan.

Ventolin can also be prescribed by hospital clinicians, walk-in centre practitioners, and authorised online prescribers registered with the General Pharmaceutical Council (GPhC) or the Care Quality Commission (CQC).

Generic salbutamol inhalers (such as Salamol and Airomir) are therapeutically equivalent to Ventolin and may be dispensed by the pharmacist unless the prescription specifies Ventolin by brand.

Repeat prescriptions can be managed through your GP surgery, the NHS App, or an authorised online pharmacy.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Patients who require multiple regular medications may benefit from a prescription prepayment certificate (PPC).

Living with asthma: practical management alongside Ventolin

Using a reliever inhaler effectively is one part of good asthma management.

To maintain optimal control, ensure you also take your preventer inhaler every day as prescribed, even when you feel well.

Keep a written personalised asthma action plan, agreed with your GP or asthma nurse, that specifies what to do when symptoms worsen.

Monitor your peak flow at home if advised. Attend annual asthma reviews. Identify and avoid your personal triggers where possible.

Ensure your inhaler technique is checked regularly, as errors develop over time even in experienced users.

Stopping smoking is the single most important lifestyle change for smokers with asthma.

Smoking directly damages the airway epithelium, accelerates lung function decline, increases exacerbation frequency, and reduces the effectiveness of inhaled corticosteroids.

The NHS offers free stop smoking services throughout the UK, accessible via your GP, pharmacy, or the NHS Smokefree helpline.

When to seek urgent medical advice

Asthma emergencies can be life-threatening.

Call 999 or attend A&E immediately if your Ventolin inhaler is not relieving your symptoms, if you are too breathless to speak, eat, or sleep, if your breathing is getting faster and it feels like you cannot get enough air, if your lips, fingernails, or skin turn blue or grey, if your peak flow is less than 50% of your personal best, or if you feel drowsy, confused, or exhausted.

While waiting for the ambulance, sit upright, try to remain calm, and take 1 puff of Ventolin every 30 to 60 seconds, up to 10 puffs.

Contact your GP or NHS 111 for non-emergency concerns, including increasing reliever use, nocturnal symptoms, or difficulty managing triggers.

Report any suspected adverse reactions to Ventolin via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Ventolin Evohaler, Summary of Product Characteristics (EMC)
• Salbutamol, British National Formulary (BNF)
• NICE NG80: Asthma: diagnosis, monitoring and chronic asthma management
• BTS/SIGN British Guideline on the Management of Asthma
• Asthma, NHS
• MHRA Yellow Card Scheme